Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Assets: 2015-2025

Historic Current Assets for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $51.5 million.

  • Seres Therapeutics' Current Assets fell 29.35% to $51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.5 million, marking a year-over-year decrease of 29.35%. This contributed to the annual value of $38.7 million for FY2024, which is 77.95% down from last year.
  • Seres Therapeutics' Current Assets amounted to $51.5 million in Q3 2025, which was up 5.84% from $48.7 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Current Assets registered a high of $358.8 million during Q3 2021, and its lowest value of $38.7 million during Q4 2024.
  • Over the past 3 years, Seres Therapeutics' median Current Assets value was $116.1 million (recorded in 2023), while the average stood at $122.7 million.
  • Per our database at Business Quant, Seres Therapeutics' Current Assets soared by 212.77% in 2021 and then tumbled by 77.95% in 2024.
  • Over the past 5 years, Seres Therapeutics' Current Assets (Quarterly) stood at $303.6 million in 2021, then tumbled by 35.85% to $194.8 million in 2022, then dropped by 9.94% to $175.4 million in 2023, then plummeted by 77.95% to $38.7 million in 2024, then declined by 29.35% to $51.5 million in 2025.
  • Its Current Assets stands at $51.5 million for Q3 2025, versus $48.7 million for Q2 2025 and $66.1 million for Q1 2025.